Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.46 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.44 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL105541 | 0.86 | GPR119 (0.53) | GPR119KDM4EMAPTTHRBPKM | |
| SCHEMBL3968317 | 0.84 | TNKS (0.49) | GPR119KDM4EMAPTTHRB | |
| SCHEMBL30721792 | 0.83 | GPR119 (0.49) | GPR119KDM4EMAPTTHRBPKM | |
| SCHEMBL29151416 | 0.83 | GPR119 (0.49) | GPR119KDM4EMAPTTHRBPKM | |
| SCHEMBL4675164 | 0.81 | TNKS (0.43) | KDM4EMAPT | |
| SCHEMBL3969511 | 0.81 | TNKS (0.46) | GPR119KDM4EMAPTTHRB | |
| SCHEMBL2211837 | 0.81 | GPR119 (0.54) | GPR119KDM4EMAPTTHRBPKM | |
| SCHEMBL19570634 | 0.80 | NAMPT (0.41) | KDM4EMAPT | |
| SCHEMBL10062680 | 0.79 | CHRM1 (0.54) | KDM4EMAPT | |
| SCHEMBL4114147 | 0.78 | MAPT (0.43) | GPR119KDM4EMAPTTHRBMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190002436-A1 | RESPIRATORY SYNCYTIAL VIRUS INHIBITORS | MEDIVIR AB (SE) | 2019-01-03 | — | — | US | disclosed |
| EP-1997805-A1 | Compounds with antiparasitic activity, applications thereof to the treatment of infectious diseases caused by apicomplexans | Commissariat à l'Energie Atomique (FR) | 2008-12-03 | — | — | EP | disclosed |
| WO-1999032481-A1 | MUSCARINIC AGENTS AND USE THEREOF TO TREAT GLAUCOMA, MYOPIA AND VARIOUS OTHER CONDITIONS | ALCON LABORATORIES, INC. (US) | 1999-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190002436-A1 | RESPIRATORY SYNCYTIAL VIRUS INHIBITORS | NR0B1, NR1I3, SCARB1 | GPR119 210/4885KDM4E 3973/4885MAPT 4269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.